How to invest in uranium as nuclear power returns
Nuclear power is back on the agenda after a decade in the doldrums. Fuel prices will be volatile, but the long-term path should be up

Nuclear power is back in the headlines. Unrest in Kazakhstan, which provides over 40% of the world’s uranium (the fuel most widely used to power nuclear plants), sent spot prices for the metal up nearly 10% to $46 per pound on 5 January. Uranium equities traded up 5%-10% on the possibility of supply disruption.
A potentially more important story got less media coverage. The European Union has said that it intends to allow nuclear-energy projects to be classified as sustainable investments. This could be very positive for demand and long-term prices – although investing in uranium is likely to be a roller-coaster ride and not for the faint-hearted.
A lost decade ends
The 2010s were a desperate decade for uranium. Back in June 2007, prices hit $136 for spot prices and $95 for long-term contracts. They then headed down to a low in October 2016 of $18.75 for spot prices and $35.50 for long-term contracts (you can find this data on the website of Cameco, one of the biggest miners.)
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The major reason was that nuclear fell from favour after the Fukushima disaster. Both Japan and Germany ditched their nuclear programmes (although Japan has now stopped plant closures). Uranium ended up in a severe supply glut, which took many years to reduce through unprecedented mine closures.
However, prices have ticked steadily higher since 2016. The political environment is changing for the better, but there is another force at work. Uranium is being financialised. There are now two funds that buy uranium (specifically, uranium oxide concentrate, known as yellow cake).
The biggest is Sprott Physical Uranium Trust (Toronto: U-UN), created in July when Sprott Asset Management took over an existing fund called Uranium Participation. This has become a market-moving force since Sprott took control. It has more than doubled in size in six months, owns almost 44 million pounds of uranium, and has a market capitalisation of US$2bn. The fund intends to raise up to $3.5bn in capital over two years, of which it had raised $1bn by November. The management cost is 0.35% per year, plus expenses, and the shares are at a 0.5% premium to the latest net asset value (NAV).
Yellow Cake (LSE: YCA) owns 19 million pounds of uranium and has a market cap of £600m, which includes around £170m in capital raised since June. It has an agreement with Kazakhstan’s Kazatomprom giving it the right to buy up to $100m per year of uranium oxide until 2027. Ongoing charges were 0.7% of NAV last year. The share price is at a discount of 10% to the latest NAV (339p) in November.
Both vehicles are a direct play on uranium prices, but also on the dynamics of the market. Utilities buy most uranium on long-term contracts and the difference between spot and contract prices can be substantial. As demand increases, more firms might have to head on to the spot markets – or pay more to secure long-term supplies. An Asian utility is said to be seeking a contract for 2025-2030 with a ceiling price of $78, according to Nick Lawson of asset-raising adviser Ocean Wall – well above current long-term prices of $43.
An even more volatile play
The alternative is to buy a fund that holds uranium miners, such as Geiger Counter (LSE: GCL). This small trust has net assets of £48m. The top four holdings are Nexgen Energy, UR-Energy, IsoEnergy, and Cameco, which account for 42% of the portfolio. The premium to latest NAV is 6% and the management charge last year was 1.38%, plus expenses.
As an investor in mining equities – which are a geared play on the commodities they produce – its shares have been more volatile. Yellow Cake has roughly doubled from its low price in March 2020, but Geiger Counter is up almost fivefold (from 10p to 48p) – yet down 35% from its November high.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Barclays begins paying up to £100 compensation to customers after banking outage
Barclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
By Daniel Hilton Published
-
Review: Shangri-La Paris – an ode to the world’s best food
Natasha Langan enjoys fine French and Chinese cuisine at the Shangri-La Paris
By Natasha Langan Published
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge Published
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge Published
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field Published
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs Published
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward Published
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves Published
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine Published
-
Pensions revolution: how to profit from the trends shaping the UK pension system
The UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
By Rupert Hargreaves Published